Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
Assessing patient-reported outcomes can support treatment for hard-to-reach populations.
Based on surveys conducted in 2015 and 2018, the number appears to have nearly tripled in San Francisco.
Among people treated for hepatitis C, diabetes and chronic kidney disease were both linked to a higher risk of cardiovascular death.
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
Premature discontinuation of hepatitis C treatment did not diminish the likelihood of sustained virological response.
Regardless of cirrhosis status, Mavyret led to high sustained virologic response rates in Latinos and other groups with hep C.
Some state Medicaid programs and prison systems still restrict treatment based on substance use or stage of liver disease.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.